Ultragenyx Pharmaceutical Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. Thank you for joining us. I'm Tazeen Ahmad. I am one of the SMID biotech analysts here at Bank of America.
It is my pleasure to introduce our next presenting company, Ultragenyx Pharmaceuticals. Speaking for Ultragenyx today is Emil Kakkis, President and CEO. Dr. Kakkis is the founder of Ultragenyx. He founded the company in 2010 to focus on developing rare and ultra-rare disease therapeutics. The company went public in January 2014, and today does have a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high-unmet medical need and a clear biology for treatment. Emil? Hello. Thanks for joining us today.
Thanks for having me, Tazeen. Happy to be here.
So for those on the webcast who may not be as familiar with Ultragenyx, maybe we could spend a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
